Loading company…
Tranzyme Pharma developed drug candidates for digestive disorders and metabolic diseases.
Tranzyme Pharma developed drug candidates for digestive and metabolic conditions, including ulimorelin, TZP-102, TZP-201, and TZP-301. Its MATCH technology was used to create synthetic libraries of macrocyclic compounds, including the HitCreate library. Founded in 1998, the company was based in North Carolina, US. In February 2012, it received USD 9.3 million in term loan proceeds through an amended debt facility with Oxford Finance LLC and Horizon Technology Finance Corporation.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in